IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Customer a | - | - | 12,474 | - |
| Other customers | - | - | 47,366 | - |
| Total net revenue | 59,952 | - | - | - |
| Research and development | 79,363 | 76,879 | 68,245 | 62,084 |
| Selling, general, and administrative | 37,699 | 43,925 | 39,553 | 39,568 |
| Cost of sales | 56,664 | 49,741 | 39,823 | 31,368 |
| Total costs and expenses | 173,726 | 170,545 | 147,621 | 133,020 |
| Amount of adjustments to revenue from contract from customer for government rebates and chargebacks | - | - | - | 51 |
| Amount of adjustments to revenue from contract from customer for other rebates, returns, discounts and adjustments | - | - | - | 545 |
| Amount of adjustments to revenue from contract from customer for wholesaler fees and cash discounts | - | - | - | 931 |
| Total net revenue | - | 49,324 | 58,555 | 31,106 |
| Loss from operations | -113,774 | -121,221 | -89,066 | -101,914 |
| Interest and other income, net | 4,104 | 3,220 | 4,005 | 3,355 |
| Net loss before income taxes | -109,670 | -118,001 | -85,061 | -98,559 |
| Income tax (expense) benefit | 1,988 | -1,838 | -1,520 | -1,458 |
| Net loss | -111,658 | -116,163 | -83,541 | -97,101 |
| Earnings per share, basic | -0.33 | -0.36 | -0.28 | -0.34 |
| Earnings per share, diluted | -0.33 | -0.36 | -0.28 | -0.34 |
| Weighted average number of shares outstanding, basic | 334,511 | 322,868 | 303,269 | 284,817 |
| Weighted average number of shares outstanding, diluted | 334,511 | 322,868 | 303,269 | 284,817 |